Post-earnings recap
Reported
Thu, May 8, 2025
EPS actual
$-0.81
EPS est.
$-0.75
EPS surprise
-7.71%
1-day move
+3.23%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a wider-than-expected loss per share, which reflects ongoing challenges in their business. However, the stock rose by 3.23% after the earnings report, likely due to investor optimism about their future clinical trials. The lack of revenue data and guidance may leave some investors cautious about the company's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.81 | N/A | -7.71% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the current quarter. They remain focused on advancing their clinical programs despite the financial losses.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the importance of upcoming clinical trials for future growth.